ACP-015
- Generic Name
- ACP-015
- Drug Type
- Biotech
- Unique Ingredient Identifier
- Y3BH8M899D
A Clinical Trial to Investigate Long-term Safety, Tolerability, and Efficacy of Weekly Subcutaneous Doses With TransCon CNP in Children and Adolescents With Achondroplasia
- First Posted Date
- 2023-07-03
- Last Posted Date
- 2024-10-07
- Lead Sponsor
- Ascendis Pharma Growth Disorders A/S
- Target Recruit Count
- 140
- Registration Number
- NCT05929807
- Locations
- 🇮🇪
Ascendis Pharma Investigational Site, Dublin, Ireland
🇵🇹Ascendis Investigational Site, Coimbra, Portugal
A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Children With Achondroplasia
Phase 2
Active, not recruiting
- Conditions
- Achondroplasia
- Interventions
- Drug: Placebo for TransCon CNP
- First Posted Date
- 2022-10-28
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- Ascendis Pharma Growth Disorders A/S
- Target Recruit Count
- 84
- Registration Number
- NCT05598320
- Locations
- 🇪🇸
Ascendis Pharma Investigational Site, Vitoria, Spain
A Dose Escalation Trial Evaluating Safety, Efficacy, and Pharmacokinetics of Multiple Subcutaneous Doses of TransCon CNP Administered Once Weekly in Children With Achondroplasia
Phase 2
Active, not recruiting
- Conditions
- Achondroplasia
- Interventions
- Drug: Placebo for TransCon CNP
- First Posted Date
- 2022-02-18
- Last Posted Date
- 2023-11-02
- Lead Sponsor
- Ascendis Pharma A/S
- Target Recruit Count
- 24
- Registration Number
- NCT05246033
- Locations
- 🇨🇳
Ascendis Pharma Investigational Site, Wuhan, China
A Dose Escalation Trial Evaluating Safety, Efficacy, and Pharmacokinetics of TransCon CNP Administered Once Weekly in Prepubertal Children With Achondroplasia
Phase 2
Completed
- Conditions
- Achondroplasia
- Interventions
- Drug: Placebo for TransCon CNP
- First Posted Date
- 2019-09-11
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- Ascendis Pharma A/S
- Target Recruit Count
- 57
- Registration Number
- NCT04085523
- Locations
- 🇵🇹
Ascendis Pharma Investigational Site, Coimbra, Portugal
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath